These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31134313)

  • 1. Differentiation of hypervascular primary hepatic tumors showing hepatobiliary hypointensity on gadoxetic acid-enhanced magnetic resonance imaging.
    Park HJ; Kim YK; Min JH; Lee J; Lee SJ; Lee ES; Ahn S
    Abdom Radiol (NY); 2019 Sep; 44(9):3115-3126. PubMed ID: 31134313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
    Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
    Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance.
    Min JH; Kim YK; Sinn DH; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Kim MJ
    Abdom Radiol (NY); 2018 Sep; 43(9):2309-2320. PubMed ID: 29470629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing "pseudo-washout" on gadoxetic acid-enhanced hepatic MRI: value of diffusion-weighted imaging in the differential diagnosis of small lesions.
    Nam SJ; Yu JS; Cho ES; Kim JH; Chung JJ
    Clin Radiol; 2017 Mar; 72(3):247-254. PubMed ID: 27789027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation.
    Lee DH; Lee JM; Lee JY; Kim SH; Kim JH; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK; Choi BI
    J Hepatol; 2015 May; 62(5):1122-30. PubMed ID: 25529623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase.
    Torrisi C; Picone D; Cabibbo G; Matranga D; Midiri M; Brancatelli G
    Eur J Radiol; 2018 Oct; 107():39-45. PubMed ID: 30292271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
    Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
    Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.
    Min JH; Kim YK; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Ahn HS
    Eur J Radiol; 2017 Jul; 92():1-10. PubMed ID: 28624005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.
    Choi SY; Kim YK; Min JH; Kang TW; Jeong WK; Ahn S; Won H
    Eur Radiol; 2018 Jun; 28(6):2549-2560. PubMed ID: 29335868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.
    Moon JY; Kim SH; Choi SY; Hwang JA; Lee JE; Lee J
    Jpn J Radiol; 2018 Aug; 36(8):489-499. PubMed ID: 29876721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.